🔎 Trials Near Me

Beranda › Sindrom Mielodisplastik › Kentucky

Uji klinis Sindrom Mielodisplastik di Kentucky

5 studi untuk Sindrom Mielodisplastik mencari peserta di lokasi di Kentucky.

Kota di Kentucky

Teks studi resmi (Bahasa Inggris)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  • The James Graham Brown Cancer Center at University of Louisville, Louisville
  • UofL Health Medical Center Northeast, Louisville
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06577441

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Kentucky/Markey Cancer Center, Lexington
  • The James Graham Brown Cancer Center at University of Louisville, Louisville
  • UofL Health Medical Center Northeast, Louisville
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05564390

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  • Norton Cancer Institute, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07422480

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • University of Kentucky/Markey Cancer Center, Lexington
  • Norton Children's Hospital, Louisville
Menerima pesertaFase 1/2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  • Norton Cancer Institute, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06499285

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.